Navigation Links
WuXi PharmaTech Presents the 2012 Life Science and Chemistry Awards
Date:1/30/2013

SHANGHAI, Jan. 30, 2013 /PRNewswire/ -- WuXi PharmaTech (NYSE: WX), a leading pharmaceutical, biotechnology, and medical device research and development outsourcing company with operations in China and the United States, announced the winners of its 6th annual WuXi PharmaTech Life Science and Chemistry Awards at a ceremony held on January 20, 2013.

Mr. Guowei Sang , Vice Chairman of the Standing Committee of the 11th National People's Congress and a member of the Chinese Academy of Engineering, and Ms. Zhizheng Wang, Vice Chairwoman of the 11th Chinese People's Political Consultative Conference and a member of the Chinese Academy of Sciences, presented the awards. Mr. Sang served as the Honorary Chairman of the award selection committee, which was comprised of nine distinguished experts from Chinese life science academia and industry.

Eighteen highly accomplished young scholars were honored through a rigorous and transparent selection process that began in May 2012. Winners of the Outstanding Achievements Awards included:

  • Prof. Rui Wang , School of Basic Medical Science, Lanzhou University
  • Prof. Hongyan Wang , School of Life Sciences, Fudan University
  • Prof. Qiao Wu , School of Life Sciences, Xiamen University

Winners of the Scholar Awards included:

  • Prof. Liu Cao , Translational Medicine Research Institute, China Medical University
  • Dr. Ke Ding , Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences
  • Prof. Zhike He , College of Chemistry and Molecular Sciences, Wuhan University
  • Prof. Tuo Jin , School of Pharmacy, Shanghai Jiao Tong University
  • Prof. Ke Lan , Institute Pasteur of Shanghai, Chinese Academy of Sciences
  • Prof. Lei Liu, Department of Chemistry, Tsinghua University
  • Dr. Zhijie Liu , Institute of Biophysics, Chinese Academy of Sciences
  • Prof. Zhangjie Shi, College of Chemistry and Molecular Engineering, Peking University
  • Dr. Xiaocheng Wang , National Institute of Biological Sciences
  • Dr. Xin Xie , Shanghai Institute of Materia Medica , Chinese Academy of Sciences
  • Prof. Ning Yan , School of Medicine, Tsinghua University
  • Prof. Shengyong Yang , State Key Laboratory of Biological Treatment, Sichuan University
  • Dr. Tao Ye, Shenzhen Graduate School, Peking University, and Hong Kong Polytechnic University
  • Dr. Ao Zhang, Shanghai Institute of Materia Medica , Chinese Academy of Sciences
  • Dr. Bing Zhu, National Institute of Biological Sciences

"I would like to express my gratitude to WuXi PharmaTech and the distinguished selection committee for their recognition of our research," said Prof. Hongyan Wang , one of the winners of the Outstanding Achievements Awards. "We hope that results from our research laboratories may one day benefit patients and their families."

"Congratulations to all of the award winners for their exceptional scientific accomplishments," commented Dr. Ge Li , Chairman and Chief Executive Officer of WuXi PharmaTech. "WuXi is delighted to present this award to recognize some of the brightest minds in China whose research can help our global industry to better understand diseases and find more effective cures. Advancing innovation to therapies is an enormous challenge that requires strong partnership between academia and industry. Our vision at WuXi is to build a technology and capability platform to enable anyone and any company to discover and develop drugs more efficiently and cost effectively to benefit patients in need around the world."

The WuXi PharmaTech Life Science and Chemistry Awards were originated in 2007 as the first nationwide scientific award in China established by a life science enterprise. The awards aim to foster early innovation and encourage pursuit of excellence in life science research.  During the six years since its inception, 95 scholars from more than 30 premier Chinese universities and research institutes have received awards, of whom three were later elected to the Chinese Academy of Sciences or the Chinese Academy of Engineering.

About WuXi PharmaTech

As a research-driven and customer-focused company, WuXi PharmaTech provides a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. WuXi AppTec is the name for the operating subsidiaries of WuXi PharmaTech. For more information, please visit: http://www.wuxiapptec.com.

WuXi PharmaTech's Contacts:

Ronald Aldridge , Director of Investor Relations
+1 (201) 585-2048
ron_aldridge@wuxiapptec.com

Aaron Shi , Assistant Director, Corporate Communications
+86-21-5046-4362
aaron_shi@wuxiapptec.com


'/>"/>
SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. WuXi PharmaTech Announces Shareholder Resolutions Adopted at 2012 Annual General Meeting
2. WuXi PharmaTech Celebrates Dr. Joseph Vaccas Induction into American Chemical Societys Medicinal Chemistry Hall of Fame
3. WuXi PharmaTech and Open Monoclonal Technology Announce OmniRat(TM) Antibody Collaboration
4. WuXi PharmaTech to Manufacture Ibalizumab for TaiMed Biologics
5. WuXi PharmaTech Receives GLP Certificate from SFDA for Suzhou Toxicology Facility
6. WuXi PharmaTech Announces Second-Quarter 2012 Results
7. Pharmatech Oncology Receives Phase 2 SBIR Funding for Just-In-Time Enrollment Model
8. WuXi PharmaTech Announces First-Quarter 2012 Results
9. Industry Leading Pharmaceutical News Website in-Pharmatechnologist.com Refocused and Relaunched
10. WuXi PharmaTech Files 2011 Annual Report on Form 20-F
11. Johnson & Johnson Presents Growth Strategies for Medical Devices & Diagnostics Segment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... 9, 2016 Research and Markets has announced ... report to their offering. ... The global travel vaccines market to grow at a ... covers the present scenario and the growth prospects of the global ... report considers the revenue generated from the sales of various vaccines ...
(Date:12/8/2016)... , Dec. 8, 2016 Australia Ophthalmic Lasers ... report, "Australia Ophthalmic Lasers Market Outlook to 2022", provides ... The report provides value, in millions of US dollars, ... segements - Excimer Lasers, Femtosecond Lasers and YAG Lasers. ... shares data for each of these market segements, and ...
(Date:12/8/2016)... KEY FINDINGS The global medical ... Various reasons for growth of the medical lifting sling ... chronic diseases, high recovery cost of injuries and government ... lifting sling refers to an assistive device that helps ... connect to the lift and hold the patient. It ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... 08, 2016 , ... Russ DiGilio , founder and ... #QuackGivesBack campaign which supported local breast cancer organizations during National Breast Cancer Awareness ... Back initiative, and we’re very pleased with the participation in every franchisee’s ...
(Date:12/8/2016)... , ... December 08, 2016 , ... CURE Media Group, ... and advocacy groups, has aligned with Upstage Lung Cancer in efforts to combat lung ... announcement, Michael J. Hennessy, Jr said, “CURE Media Group is honored to team up ...
(Date:12/8/2016)... Fla (PRWEB) , ... December 08, 2016 , ... ... smarter modes of access for customers and employees that are both engaging and ... 7 with Service Smart Technology, the software company revealed today its plans to ...
(Date:12/8/2016)... ... 08, 2016 , ... STAT courier is pleased to announce that due to ... they are expanding their presence in Dallas. One of the most exciting parts for ... jobs to the Dallas and Forth Worth market. STAT takes pride in treating their ...
(Date:12/8/2016)... ... December 08, 2016 , ... Vida Health, the ... Series B led by Canvas Ventures . Other investors include Nokia Growth Partners ... mobile platform to serve more consumers who are managing chronic conditions or ...
Breaking Medicine News(10 mins):